Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dana-Farber’s Belfer Institute for Applied Cancer Science to Present and Lead Sessions at the American Association for Cancer Research Annual Meeting 2012

Published: Tuesday, March 27, 2012
Last Updated: Tuesday, March 27, 2012
Bookmark and Share
The Belfer Institute of Applied Cancer Science is a fully integrated, collaborative cancer research center offering innovative drug discovery capabilities.

The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute today announced that the Institute will present data, participate in panel discussions and lead educational sessions at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2012, being held at McCormick Place in Chicago from Saturday, March 31 to Wednesday, April 4. The Belfer Institute of Applied Cancer Science is a fully integrated, collaborative cancer research center offering innovative drug discovery capabilities that range from the identification of cancer-causing genetic mutations to the full validation and selection of new drug targets. Working collaboratively together, across scientific disciplines, and closely with corporate partners, this team of distinguished faculty is driving the discovery of new cancer targets, defining the biological context of those targets and working to co-develop the next generation of novel cancer therapies.

“The Belfer Institute is honored to be presenting and speaking with top oncology researchers at the annual AACR meeting,” said Pasi Janne, M.D., Ph.D., scientific director of the Belfer Institute for Applied Cancer Science. “There has been significant recent progress made in the growth and evolution of the Institute, as evidenced by the recent appointment of Jessie English, our new head of research, and in advancing our collaborations with our strategic partners Merck and Sanofi-Aventis. The Belfer Institute is built upon a tradition of research excellence and we look forward to translating this research into a revolutionary next generation of cancer therapies.”

The Belfer Institute for Applied Cancer Science schedule at AACR is as follows:

-- On Saturday, March 31 at 8 a.m., Dr. Janne will chair the educational session, “Established and Emerging Targets in Lung Cancer.” The session will be held 8-10 a.m. in Room S105 at McCormick Place South.

-- On Monday, April 2 at 8:30 a.m., Jessie M. English, Ph.D., head of research of the Belfer Institute for Applied Cancer Science, will co-chair the professional advancement session, “WICR Career Mentoring Session.” The session will be held 8:30-10:30 a.m. in Continental Ballroom B-C at Hilton Chicago Hotel.

-- On Monday, April 2 at 4:55 p.m., Dr. Janne will be a discussant on the special symposium, “Clinical Trials Symposium 3: Clinical Trials of Novel Agents,” following the abstract presentations. The special symposium will be held 3-5:10 p.m. in Room W183 B/C at McCormick Place West.

-- On Tuesday, April 3 at 1:50 p.m., Dr. Janne will give a presentation titled “Therapeutic strategies with mutant selective EGFR kinase inhibitors.” The presentation will be held as part of the session, “Targeting the EGFR Family with Small Molecules,” being held 1-3 p.m. in Room W181 at McCormick Place West.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!